Wei L Lim

US Patent:

20140012558, Jan 9, 2014

Filed:

Jun 27, 2013

Appl. No.:

13/928430

Inventors:

Tommaso Mansi - Westfield NJ, US
Wei Keat Lim - Jersey City NJ, US
Vanessa King - Princeton NJ, US
Andreas Kremer - Wien, AT
Bogdan Georgescu - Plainsboro NJ, US
Xudong Zheng - Plainsboro NJ, US
Ali Kamen - Skillman NJ, US
Andreas Keller - Puttlingen, DE
Cord Friedrich Staehler - Hirschberg an der Bergstrasse, DE
Emil Wirsz - Furth, DE
Dorin Comaniciu - Princeton Junction NJ, US

Assignee:

SIEMENS CORPORATION - Iselin NJ
SIEMENS AG OSTERREICH - Wien
SIEMENS AKTIENGESELLSCHAFT - Munich

International Classification:

G06F 19/00

US Classification:

703 11

Abstract:

A system operating in a plurality of modes to provide an integrated analysis of molecular data, imaging data, and clinical data associated with a patient includes a multi-scale model, a molecular model, and a linking component. The multi-scale model is configured to generate one or more estimated multi-scale parameters based on the clinical data and the imaging data when the system operates in a first mode, and generate a model of organ functionality based on one or more inferred multi-scale parameters when the system operates in a second mode. The molecular model is configured to generate one or more first molecular findings based on a molecular network analysis of the molecular data, wherein the molecular model is constrained by the estimated parameters when the system operates in the first mode. The linking component, which is operably coupled to the multi-scale model and the molecular model, is configured to transfer the estimated multi-scale parameters from the multi-scale model to the molecular model when the system operates in the first mode, and generate, using a machine learning process, the inferred multi-scale parameters based on the molecular findings when the system operates in the second mode.

US Patent:

20210142868, May 13, 2021

Filed:

Nov 11, 2020

Appl. No.:

17/095562

Inventors:

- Tarrytown NY, US
Wei Keat Lim - Tarrytown NY, US

International Classification:

G16B 30/10
G16B 30/20
C12Q 1/6869
C12Q 1/70

Abstract:

The present disclosure provides methods and systems for analysis of genomic sequence information. The present disclosure provides, among other things, methods and systems for characterizing sequence conservation. As is discussed herein, certain methods and systems of the present disclosure include assignment of a similarity score to a sequence or pairwise sequence comparison based on a measure of coverage and a measure of identity between two aligned sequences.

US Patent:

20210090686, Mar 25, 2021

Filed:

Sep 25, 2020

Appl. No.:

17/032848

Inventors:

- Tarrytown NY, US
Wei Keat Lim - Scarsdale NY, US
Ruoyu Zhang - White Plains NY, US

International Classification:

G16B 25/10
G16B 40/00
G16B 5/00
G06F 7/58
G16H 10/40

Abstract:

Method to process single cell gene expression data to reveal gene-gene correlations by applying a noise regularization process to reduce the gene-gene correlation artifacts. The computer-implemented method of the present application comprises processing gene expression data for normalization or imputation, applying a noise regularization process to the normalized or imputed gene expression data, and applying gene-gene correlation calculation process to obtain correlated gene pairs. Random noises based on an expression value of a gene in a cell in an expression matrix are added to obtain a noise regularized expression matrix.

US Patent:

20190087538, Mar 21, 2019

Filed:

Sep 19, 2018

Appl. No.:

16/135913

Inventors:

- Tarrytown NY, US
Wei Keat Lim - Tarrytown NY, US

International Classification:

G06F 19/22
C12Q 1/6886
G06F 19/16
G06F 19/12
C12Q 1/6806
A61P 35/00

Abstract:

Methods for selecting a cancer patient for immunotherapy comprise establishing a total passenger gene mutation burden from a tumor of a cancer patient, generating a background distribution for the mutational burden of the tumor, normalizing the total passenger gene mutation burden against the background distribution, and categorizing the cancer patient as an immunotherapy responder when the total passenger gene mutation burden is greater than the mean of the background distribution. When the cancer patient is an immunotherapy responder, the patient may be administered an immunotherapy regimen that comprises activation/inhibition of T cell receptors that promote T cell activation and/or prolong immune cytolytic activities.